Corcept Therapeutics vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Corcept Therapeutics Incorporated (CORT)

Q3 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

August 202627 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Latest27 Jul – 29 Sep 2026

▲4

Corcept's earnings blowout and raised outlook lift the stock

Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.